|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Laboratoire d'Immunologie and Laboratoire
d'Hématologie, Institut de Biologie, Centre Hospitalier
Universitaire, Nantes, France; Blood Research Institute, The Blood
Center of Southeastern Wisconsin, Milwaukee; Departments of Cellular
Biology and Pharmacology, The Medical College of Wisconsin, Milwaukee;
and Centre National de la Recherche Scientifique Unité Mixte de
Recherche 5533, Hôpital Cardiologique, Pessac, France.
This article reports a Glanzmann thrombasthenia (GT) patient,
N.M., with a point mutation in the third cysteine-rich repeat of Integrins are heterodimeric transmembrane proteins
that mediate cell adhesion and cell migration.1-3 They are
involved in numerous fundamental biologic processes, including
development, homing, inflammation, angiogenesis, and wound healing, all
processes in which integrin function is subjected to a highly
sophisticated regulation.4-8 The platelet fibrinogen
receptor, the The biologic importance of platelet GPIIb-IIIa is underscored by an
inherited bleeding disorder, Glanzmann thrombasthenia (GT). The
hallmark of this disease is absent or severely reduced platelet
aggregation because of absence or dysfunction of the fibrinogen
receptor GPIIb-IIIa.16-19 In recent years, the molecular bases of numerous GPIIb-IIIa defects have been elucidated, leading to
the creation of a database for GT available on the Internet (www.med.mssm.edu/glanzmanndb or www.med.unc.edu/isth). In addition to
deletions, insertions, or rearrangements, several point mutations have
been identified in the GPIIb and GPIIIa genes of GT
patients.20 Among point mutations occurring in the GPIIIa
gene, some alter the function of the GPIIb-IIIa complex by disrupting
ligand binding sites (Cam or Asp119Tyr, ET or Arg214Gln, and Stras I
and CM or Arg214Trp variants).21-25 Others in the
cytoplasmic tail result in the integrin's being locked in a
low-affinity state (Ser752Pro and Arg724Ter
mutations).26,27 In contrast to naturally occurring mutations, GPIIIa mutations leading to gain of function have been experimentally induced and studied in recombinant
GPIIb-IIIa-transfected cells. Replacement of the ligand binding site
of Recent studies suggest that the cysteine-rich domain of GPIIIa might be
involved in GPIIb-IIIa activation. First, it has been known for a long
time that a mild reduction of disulfide bonds by dithiothreitol can
activate GPIIb-IIIa.31 Second, truncation of the
cysteine-rich repeats (CRRs) of GPIIIa led to recombinant GPIIb-IIIa
complexes exhibiting enhanced fibrinogen binding
capacities.32 Third, antibodies directed against LIBS in
the cysteine-rich domain of GPIIIa increased the affinity of GPIIb-IIIa
for its ligands and induced fibrinogen binding to
platelets.33 Fourth, disruption of the Cys5-Cys435
long-range disulfide bond by replacing cysteine with Ala resulted in
constitutively activated GPIIb-IIIa integrin complexes showing
high-affinity binding to immobilized fibrinogen.34,35 Fifth, the conformational changes that facilitate the shift of GPIIb-IIIa from a resting state to an activated state involved the
regions in GPIIIa brought into proximity by the Cys5-Cys435 bond.36 Furthermore, the resting conformation of
GPIIb-IIIa displays 2 to 3 unpaired cysteines, whereas the activated
conformation has 4 to 5 free cysteines.37 Sixth, a
Thr562Asn mutation located in the cysteine-rich core of GPIIIa
identified during a screening of Chinese hamster ovary (CHO) cell
transfectants gave rise to the expression of an activated GPIIb-IIIa
receptor.38 The rationale for the implication of the
GPIIIa CRR region in integrin activation is based on the emerging
concept that the redox state of cysteine-containing molecules could
regulate their biologic activity. Protein disulfide isomerase
(PDI) is well known for assisting proteins in folding during
biosynthesis by catalyzing disulfide rearrangements in intracellular
compartments.39 PDI has also been reported to participate
in rearrangements of disulfide bonds in adjacent proteins on the
external surface of platelets and to be involved in In this context, we report a novel case of GT in which a homozygous
point mutation of Cys560 within the GPIIIa cysteine-rich domain
resulted in a GPIIb-IIIa receptor locked in a high-affinity state.
Case report
Antibodies
Platelet glycoprotein analysis by flow cytometry Platelet-rich plasma (PRP) was obtained by centrifugation of acid-citrate-dextrose-anticoagulated blood at 240g for 10 minutes, and platelets were isolated from PRP supplemented with 10 7 M prostaglandin E1 (PGE1) by
centrifugation at 2500g for 8 minutes. The pellet was washed
twice with RCD buffer (108 mM NaCl, 3.8 mM KCl, 1.7 mM
NaHCO3, 21.2 mM sodium citrate, 27.8 mM glucose, pH 6.5, containing 107 M PGE1). For platelet
activation studies, no PGE1 was added to the final wash.
Surface expression of GPIIb-IIIa was assessed by incubating 106 washed platelets with AP3, SZ22, 6E1, and SZ1, followed by FITC-conjugated goat anti-mouse IgG F(ab')2 (BioAtlantic). The cells were washed twice and analyzed on a FACScan (Becton Dickinson). To study the adhesive properties of the patient's GPIIb-IIIa, we
incubated FITC-fibrinogen50 and FITC-PAC-1 with platelets in Tyrode-HEPES buffer51 supplemented with 2 mM
CaCl2 and 1 mM MgCl2. Platelets were fixed in
phosphate-buffered saline (PBS)-1% formaldehyde and subjected to flow
cytometry. Ligand binding was expressed as an activation index (AI),
defined as (Fx To assess LIBS exposure on N.M.'s platelets, we incubated PRP
supplemented with 10 To assess fibrinogen binding to platelets in vivo, we incubated 5 µL
freshly drawn citrated blood with FITC-conjugated rabbit anti-human
fibrinogen (Dako, Trappes, France). Binding was studied in the presence
of saturating concentrations of anti-Fc Semiquantitative analysis of total platelet GPIIb-IIIa content by Western blotting Sodium dodecyl sulfate (SDS) platelet lysates were resolved by SDS-polyacrylamide gel electrophoresis under reducing conditions. Proteins were transferred to polyvinylidene difluoride (PVDF) membrane, and the blot was incubated with polyclonal antibody specific for GPIIb or GPIIIa.Electron microscopy Platelet preparation. Blood from the patient or a control donor was obtained by venipuncture and placed in 3.8% (wt/vol) sodium citrate. The initial 3 mL of blood was discarded. PRP was prepared by centrifugation at 120g for 10 minutes at room temperature. One part of the PRP was stimulated with 50 µM thrombin receptor activating peptide 6 (TRAP6) (Bachem) for 5 minutes at 37°C; incubations were not stirred after the initial mixing. Samples were then fixed in 1.25% wt/vol glutaraldehyde diluted in 0.1 M phosphate buffer. Immunogold labeling before embedding. Glutaraldehyde-fixed platelets were incubated with rabbit antifibrinogen antibody (Dako, Copenhagen, Denmark). After washing, the samples were incubated with affinity-purified goat anti-rabbit IgG coupled to 10-nm gold particles (Amersham, Les Ulis, France). Platelets were postfixed, dehydrated, and finally embedded in Epon (Taab Laboratories, Reading Berks, United Kingdom). Ultrathin sections were cut with an Ultracut E ultramicrotome (Reichert, Vienna, Austria) and stained before being observed in a Jeol JEM-1010 electron microscope (Jeol, Croissy-sur-Seine, France) at 80 kV.53 Platelet aggregation following TRAP-induced secretion and mobilization of the internal GPIIb-IIIa pool Platelet aggregation was performed using citrated PRP (2 × 108 platelets/mL), which was stirred in the aggregometer before addition of TRAP6. After maximal aggregation, samples were removed and centrifuged for 30 minutes at 2500g. Release of platelet factor-4 (PF4, a platelet -granule protein) into the supernatant was quantified by
enzyme-linked immunosorbent assay (ELISA) using an anti-PF4 antibody
(Asserachrom kit; Asnières-sur-Seine, France). To evaluate GPIIb-IIIa expression at the surface, we incubated 106
TRAP6-stimulated platelets with FITC-conjugated 6E1 and analyzed them
by flow cytometry.
Platelet adhesion and spreading on fibrinogen Coating was performed with 100 µg/mL purified fibrinogen (Kordia, Leiden, The Netherlands) or 5 mg/mL bovine serum albumin (BSA) in 3 mL PBS per dish (Cofralab, Gradignan, France) overnight at 4°C; dishes were then blocked with 5 mg/mL PBS-BSA at room temperature for 2 hours. Platelets were isolated by gel-filtration as described previously.27 To prevent platelet activation, 107 M PGE1 and 1 U/mL apyrase were present
during the gel-filtration. One milliliter volume
(3 × 108 platelets) was added to each dish and incubated
for 90 minutes at 37°C. After 2 washes with cold PBS to discard
nonadherent platelets, platelet adhesion and spreading were observed by
phase microscopy.
Nucleotide sequence analysis of GPIIb and GPIIIa from genomic DNA All 30 exons and immediate flanking sequences of the GPIIb gene, and all 15 exons and immediate flanking sequences of the GPIIIa gene, were amplified by polymerase chain reaction (PCR) using well-established methods. Amplified DNA fragments were purified and subjected to direct cycle sequence analysis using automated sequencing (Applied Biosystems, Foster City, CA).Site-directed mutagenesis of GPIIIa cDNA The mutation corresponding to that found in the GPIIIa gene of the patient was introduced into full-length GPIIIa cDNA using a mismatched primer corresponding to the GPIIIa cDNA sequence for Arg at position 560 (5'-TACTACTGCAACCGTACCACGCGTA-3'). After secondary PCR, the cDNA fragment containing the mutation was cloned into mammalian expression vector pcDNA3, which contains a neomycin resistance gene (Invitrogen, San Diego, CA). The sequence of all constructs was analyzed using automated sequencing (Applied Biosystems).Cell line transfections CHO cells were cultured in alpha-minimum essential medium (MEM) with ribo- and deoxyribonucleotides containing 10% fetal calf serum. CHO cells were cotransfected with GPIIb cDNA in the mammalian expression vector EMC-3 and wild-type GPIIIa (WT GPIIb-IIIa) or Arg560GPIIIa (GPIIb-Arg560IIIa) in pcDNA3 using the calcium phosphate method. EMC-3, which contains a methotrexate resistance gene, was a gift of Dr Larsen (Genetics Institute, Boston, MA). After 48 hours, transfected CHO cells were selected in alpha-MEM without ribo- or deoxyribonucleotides containing 600 µg/mL geneticin (Gibco, Gaithersburg, MD) for 2 weeks. To obtain stable cell lines with high levels of expression, transfected CHO cells were sorted in a FACStar (Becton Dickinson) using AP3, cloned by limiting dilutions, and maintained in selection media containing 5 nM methotrexate.Flow cytometric analysis of recombinant GPIIb-Arg560IIIa CHO cells were harvested, washed, and incubated on ice with AP3 and AP2, then washed and incubated with FITC-conjugated goat anti-mouse IgG (Jackson, West Grove, PA). LIBS and PAC-1 antibodies were incubated for 45 minutes at room temperature, and then binding to cells was assessed using FITC-conjugated anti-IgG or anti-IgM (Jackson) for 30 minutes and subjected to flow cytometric analysis.
Initial screening showed that N.M. has a GT-like phenotype The patient's bleeding time is typically markedly prolonged (more than 20 minutes; Ivy method) despite his mild bleeding tendency. The closure time measured with the platelet-function analyzer 100 (PFA-100; Dade Behring, Paris La Défense, France) was infinite with both ADP or epinephrine cartridges. Platelet aggregation in PRP was markedly impaired in response to usual concentrations of physiologic agonists, including 1 to 5 µM ADP (0% aggregation), 0.25 µg/mL arachidonic acid (30%), 100 µM epinephrine (0%), and 1.5 and 3 µg/mL collagen (0 and 10%, respectively) (data not shown). However, ristocetin (0.8-2 mg/mL) induced normal aggregation. Whole blood and plasma clot retraction were markedly reduced (data not shown).The presence of glycoproteins on N.M.'s platelets was analyzed by flow
cytometry. The surface expression of GPIIb-IIIa was about 20% of
normal, whereas GPIb (93%) was normally expressed (Figure
1A). Because the binding of the
complex-specific antibody, 6E1, was similar to that of subunit-specific
antibodies, GPIIb and GPIIIa in N.M.'s platelets appeared to associate
correctly to form an integrin complex. Furthermore, the complexes
appeared stable because attempts to dissociate them with increasing
concentrations of EDTA at room temperature failed to prematurely
separate the GPIIb and GPIIIa subunits (data not shown). To estimate
the total platelet content of GPIIb and GPIIIa, we performed Western
blot analysis with polyclonal antibodies specific for each subunit. Interestingly, N.M.'s platelets contained more GPIIb and GPIIIa than
would have been predicted from the surface expression, with levels
ranging from 50% to subnormal compared with control platelets (Figure
1B). The platelet fibrinogen content was similar to that of control
platelets, as determined by immunostaining with antifibrinogen antibody
(data not shown).
The patient's platelets express a constitutively activated form of GPIIb-IIIa Because some GPIIb-IIIa was detectable at the platelet surface, we assessed its ability to bind FITC-conjugated PAC-1. Although care was taken to prevent platelet activation during the preparation procedures, we observed a spontaneous binding of FITC-labeled PAC-1 to resting patient's platelets, but not to resting control platelets (Figure 2A). The AI was calculated as follows: 0.270 ± 0.067 (n = 3) for N.M. versus 0.040 ± 0.029 (n = 3) for the control. Platelets from N.M. also spontaneously bound FITC-fibrinogen (Figure 2B); the AI was calculated to be 0.220 ± 0.140 (n = 3) for the patient versus 0.027 ± 0.005 (n = 3) for the control. Because the patient's platelets expressed only about 20% of the normal amount of GPIIb-IIIa, PAC-1 and fibrinogen binding would be much greater with a normal platelet density of mutated GPIIb-IIIa.
To evaluate further the competent conformation of the patient's
GPIIb-IIIa for ligand, we performed flow cytometric analysis for LIBS
exposure by incubating anti-LIBS antibodies 7D6, D3, and AP5 with
N.M.'s platelets in PRP and in the presence of 2 mM RGDS or RGES
peptides. The LIBS index obtained with 7D6, AP5, or D3 in the absence
of RGDS peptide was much greater for N.M. (0.88, 0.63, and 0.78, respectively) compared with the corresponding values obtained for
control platelets (0.16, 0.06, and 0.14, respectively) (Figure
3). This demonstrates that LIBS are
constitutively exposed on the patient's GPIIb-IIIa without a
requirement for agonist stimulation. Incubation of N.M.'s platelets
with RGDS peptide did not cause further LIBS expression. This suggests
that all of the surface GPIIb-IIIa of the patient's platelets is
already in a ligand binding competent state.
The spontaneously activated state of N.M.'s GPIIb-IIIa receptor would
predict that some fibrinogen might be present on the surface of his
circulating platelets in vivo. To assess the presence of fibrinogen on
N.M.'s platelets, we used the micromethod described by Warkentin et
al.52 An antifibrinogen antibody was used to detect bound
fibrinogen in the presence of excess of soluble plasma fibrinogen. At
least twice the amount of bound fibrinogen was detected on N.M.'s
platelets compared with control platelets (Figure 4). The MFIs indicated in Figure 4 do not
take into account the reduced GPIIb-IIIa expression on N.M.'s
platelets. GPIIb-IIIa expression at the cell surface was assessed in
parallel with SZ22, an anti-GPIIb antibody, and is also shown in Figure
4.
The presence of a spontaneously activated GPIIb-IIIa receptor at the surface of N.M.'s platelets was further demonstrated when washed platelets were incubated with fibrinogen in an aggregometer cuvette. In the absence of stirring, no aggregates were observed; however, when stirring was initiated, microaggregates started to form, although a full macroscopic platelet aggregation was not achieved (data not shown). This observation indicates that fibrinogen is able to bind to its receptor without previous platelet activation and that this interaction could mediate a primary platelet-to-platelet interaction under stirring. In vivo, we were not able to find any microaggregates in the patient's PRP or on his blood smears. Taken together, these data demonstrate that N.M.'s platelets constitutively display a receptor expressed in a competent conformation for ligand binding. Platelet morphology and immunocytochemical studies N.M.'s platelets mostly showed normal morphology, although increased size heterogeneity was noted. They were discoid with a full granule content (Figure 5B). When viewed on a broad field, immunogold staining for fibrinogen was globally increased at the platelet surface compared with control platelets. Although the labeling of some platelets (Figure 5B) resembled the control, others had an impressive concentration of gold particles at their surface (Figure 5C). The pattern of labeling for N.M. was distinctive, with clusters of gold particles at discrete intervals. Such a pattern was never seen for unstimulated control platelets (Figure 5A). In the illustrated platelet, we also noted the presence of enlarged vacuoles or distended channels (Figure 5C). Their presence was not a prerequisite for fibrinogen labeling at the surface. Note that the channels themselves did not contain gold beads. Although this may mean that the antibodies did not access this compartment in pre-embedded platelets, no signs of fibrinogen accumulation in the surface-connected canalicular system were seen when labeling was performed on frozen-thin sections (data not shown). After activation of N.M.'s platelets with TRAP6, shape change and secretion normally occurred. The quantity of fibrinogen detected on the surface of N.M.'s platelets increased globally. Some platelet aggregates were formed for the control even in the absence of continuous stirring (Figure 5D). For the patient, in contrast, only groups of 2 or 3 platelets were seen, despite immunogold labeling for fibrinogen on the surface (Figure 5E).
Patient N.M. possesses a novel mutation within the cysteine-rich domain of GPIIIa Direct sequence analysis of PCR-amplified fragments representing the coding sequences of the GPIIb and GPIIIa genes and the splice sites from patient N.M. revealed a homozygous g1776T>C substitution within exon 10 of the GPIIIa gene, which results in a Cys560Arg mutation located in the cysteine-rich domain of GPIIIa (Figure 6).
Expression of recombinant GPIIb-Arg560IIIa on the surface of transfected CHO cells To further examine the effect of the Cys560Arg mutation on the processing and the function of GPIIb-IIIa, we constructed an expression vector encoding Arg560GPIIIa using site-directed mutagenesis and cotransfected it with wild-type (WT) GPIIb cDNA into CHO cells. After cell sorting, a stable cell line was obtained expressing the mutated complex (see "Patient, materials, and methods"). The expression of the GPIIb-Arg560IIIa complex on the cell surface was analyzed by flow cytometry using the anticomplex antibody AP2 and the antisubunit GPIIIa AP3 (Figure 7). These 2 antibodies specifically stained CHO cells expressing WT GPIIb-IIIa and GPIIb-Arg560IIIa, and the MFIs were similar for both antibodies. These data confirm that the Cys560Arg mutation does not affect the ability of GPIIIa to associate with GPIIb.
Assessment of LIBS exposure on recombinant GPIIb-IIIa To examine whether the Cys560Arg mutation produces spontaneous LIBS exposure on GPIIb-IIIa at the CHO cell surface, as was observed for the patient's platelets, we incubated transfected CHO cells with AP5, CRC54, D3, and 7D6 LIBS antibodies and then performed flow cytometric analysis. As shown in Figure 8A, the binding of LIBS antibodies to CHO cells expressing WT GPIIb-IIIa was low relative to that observed for the non-LIBS antibody AP3. However, the binding of LIBS antibodies AP5, D3, CRC54, and 7D6 to CHO cells expressing GPIIb-Arg560IIIa was increased (LIBS index [LI] = 0.7, 0.4, 0.75, and 0.2, respectively) compared with WT transfected cells (LI = 0.15, 0.1, 0.2, and 0.02, respectively). These results confirm that the conformation of the GPIIb-Arg560IIIa complex is modified by the Cys560Arg mutation.
To assess the ability of the GPIIb-Arg560IIIa complex to bind ligand, we examined the binding of PAC-1 to transfected CHO cells (Figure 8B). Although PAC-1 did not bind to CHO cells expressing WT GPIIb-IIIa (MFI = 3.7), PAC-1 binding to CHO cells expressing GPIIb-Arg560IIIa complex was dramatically increased (MFI = 120). Binding was specific because it was totally inhibited with excess RGDW peptide (Figure 8B). These data confirm that the ligand binding pocket is constitutively exposed in the GPIIb-Arg560IIIa complex. Capacity for N.M.'s platelets to aggregate after secretion of the GPIIb-IIIa internal pool Because we have shown that N.M.'s platelets contained significant total amounts of GPIIb-IIIa, we wondered whether aggregation was improved after TRAP6-induced-granule secretion. Platelets in PRP
were stimulated with 50 µM TRAP6, and expression of GPIIb-IIIa at the
platelet surface was assessed with an anti-GPIIb-IIIa antibody (Figure
9A). The patient's platelets expressed
significantly more GPIIb-IIIa after stimulation, confirming the
exposure of at least a part of the internal pool. This allowed the
platelets to undergo a modified aggregation, which reached a maximum
intensity of 40% despite a lower initial velocity (Figure 9B). Under
similar conditions, the maximal aggregation of the control was 84%, a
value also achieved when platelets were activated with lower
amounts of TRAP6 (7 µM) (Figure 9B). When very high concentrations of
other agonists were used, such as 100 µM ADP or 9 µg/mL collagen,
N.M.'s platelets showed some residual aggregation but again with a
reduced velocity (data not shown).
N.M.'s platelets and GPIIb-Arg560IIIa-transfected CHO cells are able to adhere to and spread on fibrinogen matrix Previous studies have shown that normal platelets can adhere to immobilized fibrinogen without prior agonist activation.27,54 Adhesion assays with N.M.'s platelets were performed on dishes coated with 100 µg/mL fibrinogen during 90 minutes. After washing, adherent cells were examined by phase microscopy. N.M.'s platelets normally adhered to and spread on the fibrinogen matrix, adopting the typical fried-egg appearance (Figure 10).
In the same way, it has been shown previously that GPIIb-IIIa-expressing CHO cells can bind to a fibrinogen matrix.37,55 The adhesive properties of the GPIIb-Arg560IIIa complex were analyzed by examining the ability of transfected CHO cells to adhere to immobilized fibrinogen. The most striking difference in adhesion could be seen at an early time point (15 minutes), when twice as many CHO cells expressing the GPIIb-Arg560IIIa complex bound to 2 µg/mL immobilized fibrinogen compared with the WT transfected cells (data not shown). Cell spreading was also examined, and the Cys560Arg mutation imparted increased spreading capacities to GPIIb-IIIa-transfected CHO cells compared with CHO cells expressing WT GPIIb-IIIa at 15, 30, 60, and 90 minutes. The increased capacity for spreading was again most significant at 15 minutes, whereas it tended to decrease with time (data not shown).
We report here the identification of a novel mutation in GPIIIa from a patient (N.M.) with a GT-like phenotype that produces a receptor locked in a high-affinity state and able to bind fibrinogen. We first diagnosed the patient as having GT on the basis of severely impaired platelet aggregation in PRP in response to physiologic agonists, abnormal clot retraction, and a prolonged bleeding time. Analysis of cell-surface GPIIb-IIIa showed an approximate 80% reduction in the expression of the integrin. Unexpectedly, the surface-expressed GPIIb-IIIa appeared to be locked in a high-affinity state constitutively expressing LIBS epitopes and spontaneously binding PAC-1 and fibrinogen. The molecular basis of this defect was elucidated. Sequence analysis of PCR fragments derived from N.M.'s genomic DNA revealed a homozygous g1776T>C nucleotide substitution leading to a Cys560Arg mutation in the GPIIIa subunit. This amino acid substitution occurs within the third CRR of GPIIIa. Like other integrin We found that the Cys560Arg mutation leads to a GPIIb-IIIa receptor that exists in a high-affinity ligand binding state. It is tempting to speculate that replacement of Cys560 leads to disulfide-bond rearrangements that mimic activation of the integrin. Replacement of Cys560 might result in exposure of a free thiol at residue 567 or another cysteine elsewhere, increasing the association rate of GPIIb-IIIa with its ligand. It is noteworthy that neither Cys560 nor its putative Cys567 counterpart forms part of the CGXC consensus sequence associated with PDI-like activity43 or the CD/E motif recognized by NO in nitrosylations59,60; both processes are involved in regulation of redox states for integrin activation.41,42,57,58 Nonetheless, both the PDI and nitrosylation sites are relatively close to Cys560 and Cys567 in the linear sequence (Cys544-Gly-Asp-Cys547 and Cys581-Glu-Cys583, respectively), and they might be even closer in a tertiary structure, such that mutation of residue 560 could perturb disulfide rearrangements in this area and subsequently interfere with PDI and nitrosylation activities. Not all mutations involving cysteine residues in the CRRs of GPIIIa lead to the production of an activated receptor. Arg636Cys and Cys655Tyr mutations have no apparent effect on GPIIb-IIIa biosynthesis or function.61,62 In contrast, Cys457Tyr, Cys506Tyr, and Cys542Arg mutations interfere with the expression of the GPIIb-IIIa complex on the platelet plasma membrane.63-65 Similarly, the Cys374Tyr mutation leads to a severely decreased expression of GPIIb-IIIa on the platelet surface, although the integrin complexes that become surface expressed appear to retain the ability to mediate adhesion to immobilized fibrinogen.66 These authors also found a decreased capacity of transiently transfected CHO cells to express the mutated integrin despite a normal transcription of the cDNA constructs. We also observed a reduced expression (approximate 60% reduction) of GPIIb-Arg560IIIa in stably transfected CHO cells before selection for high expression by sorting and cloning (C.-Y.L., Q.-H.S., and P.J.N., unpublished data, 1999). Significantly, we have also shown that the Cys5Ala and Cys435Ala forms of GPIIIa exhibit an increased affinity for immobilized fibrinogen.34,35 Involvement of the Cys5-Cys435 bond in GPIIb-IIIa activation has been reinforced lately by structural studies of resting and activated conformations of GPIIb-IIIa.36 Interestingly, the neighboring Thr562Asn mutation does not target a cysteine but produces an active GPIIb-IIIa complex.38 Not all substitutions at residue 562 result in receptor activation, as neither Thr562Ala nor Thr562Gln forms of GPIIIa are "on," supporting the notion that the nature of the amino acid substitution might be important. In this regard, Ambo et al67 reported a Phe residue substituted for a cysteine at the same position 560 as in patient N.M. It would be of interest to know whether this particular amino acid change results in the expression of a constitutively activated complex. It is intriguing that expression of a constitutively activated GPIIb-IIIa receptor leads to a mild bleeding tendency instead of a prothrombotic phenotype. Similar observations have been made in the rare platelet-type von Willebrand disease (PT-vWD), in which bleeding symptoms and prolonged bleeding times are the result of mutations leading to heightened interaction of von Willebrand factor (vWF) with its receptor, GPIb.68 Thus, in both cases there is an up-regulation of the activation state of the receptor for its ligand. The parallel between N.M. and PT-vWD phenotypes could be extended because the mutations responsible for the increased vWF-GPIb interaction target residues located in disulfide-bonded loops in the N-terminal domain of GPIb known to be involved in the ligand binding itself or in its regulation.69-71 Nevertheless, whereas N.M.'s platelets are unable to aggregate normally even with high doses of suitable agonists, the platelets of PT-vWD patients display an enhanced aggregation in response to low doses of ristocetin, although leading to a bleeding phenotype by platelet adsorption of the high-molecular-mass vWF multimers that are the most effective for platelet adhesion.71 In the present study, it is important to note that despite a receptor constitutively expressed in a high-affinity conformation and occupied by fibrinogen, N.M.'s platelets did not display consistent signs of activation when examined by electron microscopy. A possible explanation for failure of this activated integrin to lead to cellular activation may be the reduced amount (approximately 20%) of GPIIb-IIIa present on the platelet surface. We observed that when N.M.'s platelets expressed increased amounts of GPIIb-IIIa, as after TRAP stimulation, the aggregation response improved. This is in agreement with the hypothesis that the low number of GPIIb-IIIa complexes on the circulating platelet surface is a limiting factor in the formation of the protein bridges necessary for platelet aggregation. Indeed, a facilitated binding of fibrinogen may lead to a high concentration of monovalently bound ligand unable to find an unoccupied counterreceptor. This would be particularly so in plasma where fibrinogen concentrations are high. Additionally, immunogold labeling with both antifibrinogen antibody (Figure 5) and antibody to GPIIb-IIIa complexes (data not shown) suggested that the residual surface-bound complexes are distributed heterogeneously within the total population of N.M.'s platelets. Thus, some platelets may not be able to support aggregation even when stimulated by a strong agonist. The capacity of the patient's platelets as well as
GPIIb-Arg560IIIa-transfected CHO cells to spread on a
fibrinogen-covered surface demonstrates that despite the Cys560Arg
mutation, the patient's GPIIb-IIIa complexes are still able to
participate in outside-in signaling. The complexes are also able to
transport fibrinogen, as the patient's In conclusion, the description of this novel case of Glanzmann thrombasthenia provides a new model to study the regulation of integrin activation through thiol bonding modifications in ectodomains independently from cytoplasmic inside-out signaling. Besides, the gain-of-binding mutation described in this GT patient may help to further understand complex molecular relations between GPIIb-IIIa receptor activation and integrin-mediated platelet aggregation and requirements for cellular adhesion events.
We are grateful to N.M. for generously donating his time to this project. We thank Drs Jennings, Mazurov, Shattil, and Blanchard for the generous supply of monoclonal antibodies. We also thank Drs Hourmant and Dantal as well as the transplantation unit in Nantes.
Submitted April 5, 2001; accepted June 5, 2001.
Supported by grant R01 HL-44612 from the National Institutes of Health (P.J.N.) and a grant from the Agence Française du Sang (FORTS 95000440744) (N.V.).
C.R. and C.-Y.L. contributed equally to this article.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Nathalie Valentin, Laboratoire d'Immunologie, Institut de Biologie, 9, quai Moncousu, 44093 Nantes Cedex 01, France; e-mail: nathalie.valentin{at}chu-nantes.fr.
1. Hynes RO. Integrins: a family of cell surface receptors. Cell. 1987;48:549-554[CrossRef][Medline] [Order article via Infotrieve]. 2. Ruoslahti E. Integrins. J Clin Invest. 1991;87:1-5. 3. Hynes RO. Integrins: versatility, modulation and signaling in cell adhesion. Cell. 1992;69:11-25[CrossRef][Medline] [Order article via Infotrieve].
4.
McDonald JA.
Integrins minireview series.
J Biol Chem.
2000;275:21783
5.
Plow EF, Haas TA, Zhang L, Loftus J, Smith JW.
Ligand binding to integrins.
J Biol Chem.
2000;275:21785-21788
6.
Calderwood DA, Shattil SJ, Ginsberg MH.
Integrins and actin filaments: reciprocal regulation of cell adhesion and signaling.
J Biol Chem.
2000;275:22607-22610
7.
Harris ES, McIntyre TM, Prescott SM, Zimmerman GA.
The leucocyte integrins.
J Biol Chem.
2000;275:23409-23412
8.
Woods A, Couchman JR.
Integrin modulation by lateral association.
J Biol Chem.
2000;275:24233-24236 9. Shattil SJ. Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost. 1995;74:149-155[Medline] [Order article via Infotrieve]. 10. Ginsberg MH, Du X, O'Toole TE, Loftus JC. Platelet integrins. Thromb Haemost. 1995;74:352-359[Medline] [Order article via Infotrieve]. 11. Shattil SJ, Ginsberg MH, Brugge JS. Adhesive signaling in platelets. Curr Opin Cell Biol. 1994;6:695-704[CrossRef][Medline] [Order article via Infotrieve]. 12. Ginsberg MH, Du X, Plow EF. Inside-out integrin signalling. Curr Opin Cell Biol. 1992;4:766-771[CrossRef][Medline] [Order article via Infotrieve]. 13. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood. 1998;9:2645-2657. 14. Du X, Plow EF, Frelinger AL III, O'Toole TE, Loftus JC, Ginsberg MH. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell. 1991;65:409-416[CrossRef][Medline] [Order article via Infotrieve].
15.
Frelinger AL III, Lam SCT, Plow EF, Smith MA, Loftus JC, Ginsberg MH.
Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion.
J Biol Chem.
1988;263:12397-12402 16. Glanzmann E. Hereditare hamorrhagische thrombasthenie: ein beitrag zur pathologie der blut plattchen. J Kinderkr. 1918;88:1-13. 17. Nurden AT, Caen JP. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br J Haematol. 1974;28:253-260[Medline] [Order article via Infotrieve]. 18. Nurden AT, Caen JP. Specific roles for platelet surface glycoproteins in platelet function. Nature. 1975;55:720-722. 19. Phillips DR, Agin PP. Platelet membrane defects in Glanzmann's thrombasthenia: evidence for decreased amounts of two major glycoproteins. J Clin Invest. 1977;60:535-545. 20. Newman PJ, Poncz M. Inherited disorders of platelets. In: Scriver CR,Beaudet AL,Sly WS,Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill; 1995:3335-3366.
21.
Loftus JC, O'Toole TE, Plow EF, Glass A, Frelinger AL III, Ginsberg MH.
A beta 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation.
Science.
1990;249:915-918
22.
Bajt ML, Ginsberg MH, Frelinger AL III, Berndt MC, Loftus JC.
A spontaneous mutation of integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site.
J Biol Chem.
1992;267:3789-3794 23. Lanza F, Stierlé A, Fournier D, et al. A new variant of Glanzmann's thrombasthenia (Strasbourg I): platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg--214Trp mutation. J Clin Invest. 1992;89:1995-2004. 24. Nurden AT, Rosa JP, Fournier D, et al. A variant of Glanzmann's thrombasthenia with abnormal glycoprotein IIb-IIIa complexes in the platelet membrane. J Clin Invest. 1987;79:962-969.
25.
Djaffar I, Rosa JP.
A second case of variant Glanzmann's thrombasthenia due to substitution of platelet GPIIIa (integrin
26.
Chen YP, Djaffar I, Pidard D, et al.
Ser-752 27. Wang R, Shattil SJ, Ambruso DR, Newman PJ. Truncation of the cytoplasmic domain of beta3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin alpha(IIb) beta3 complex. J Clin Invest. 1997;100:2393-2403[Medline] [Order article via Infotrieve].
28.
Bajt ML, Loftus JC, Gawaz MP, Ginsberg MH.
Characterization of a gain of function mutation of integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa).
J Biol Chem.
1992;267:22211-22216
29.
O'Toole TE, Mandelman D, Forsyth J, Shattil SJ, Plow EF, Ginsberg MH.
Modulation of the affinity of integrin alpha IIb beta 3 (GPIIb-IIIa) by the cytoplasmic domain of alpha IIb.
Science.
1991;254:845-847
30.
Hughes PE, Diaz-Gonzalez F, Leong L, et al.
Breaking the integrin hinge: a defined structural constraint regulates integrin signaling.
J Biol Chem.
1996;271:6571-6574 31. Zucker MB, Masiello NC. Platelet aggregation caused by dithiothreitol. Thromb Haemost. 1984;51:119-124[Medline] [Order article via Infotrieve].
32.
Wippler J, Kouns WC, Schlaeger EJ, Kuhn H, Hadvary P, Steiner B.
The integrin alpha IIb-beta 3, platelet glycoprotein IIb-IIIa, can form a functionally active heterodimer complex without the cysteine-rich repeats of the beta 3 subunit.
J Biol Chem.
1994;269:8754-8761
33.
Frelinger AL III, Du X, Plow EF, Ginsberg MH.
Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function.
J Biol Chem.
1991;266:17106-17111 34. Liu CY, Sun QH, Wang R, Paddock CM, Newman PJ. Disruption of the long-range GPIIIa Cys5-Cys435 disulfide bond results in the production of a constitutively active GPIIb-IIIa integrin complex [abstract]. Blood. 1997;90:573a. 35. Liu CY, Sun QH, Wang R, Paddock CM, Newman PJ. Further examination of the role of GPIIIa long-range Cys5-Cys435 disulfide bond in conformational changes of GPIIb-IIIa: substitution of cysteine 5 with alanine results in the production of a constitutively active GPIIb-IIIa integrin complex [abstract]. Blood. 1998;92:344a.
36.
Yan B, Hu DD, Knowles SK, Smith JW.
Probing chemical and conformational differences in the resting and active conformers of platelet integrin
37.
Yan B, Smith JW.
A redox site involved in integrin activation.
J Biol Chem.
2000;275:39964-39972
38.
Kashiwagi H, Tomiyama Y, Tadokoro S, et al.
A mutation in the extracellular cysteine-rich repeat region of the beta3 subunit activates integrins alphaIIbbeta3 and alphaVbeta3.
Blood.
1999;93:2559-2568
39.
Gilbert HF.
Protein disulfide isomerase and assisted protein folding.
J Biol Chem.
1997;272:29399-29402 40. Essex DW, Chen K, Swiatkowska M. Localization of protein disulfide isomerase to the external surface of the platelet plasma membrane. Blood. 1995;86:2163-2173. 41. Lahav J, Gofer-Dadosh N, Luboshitz J, Hess O, Shaklai M. Protein disulfide isomerase mediates integrin-dependent adhesion. FEBS Lett. 2000;475:89-92[CrossRef][Medline] [Order article via Infotrieve].
42.
Burgess JK, Hotchkiss KA, Suter C, et al.
Physical proximity and functional association of glycoprotein Iba and protein-disulfide isomerase on the platelet plasma membrane.
J Biol Chem.
2000;275:9758-9766
43.
O'Neil S, Robinson A, Deering A, Ryan M, Fitzgerald DJ, Moran N.
The platelet integrin
44.
Kouns WC, Wall CD, White MM, Fox CF, Jennings LK.
A conformation-dependent epitope of human platelet glycoprotein IIIa.
J Biol Chem.
1990;265:20594-20601 45. de Haas M, von dem Borne AEGK. CD41/CD61 workshop panel report. In: Kishimoto T,Kikutani H,von dem Borne AEGK, et al., eds. Leucocyte Typing VI: White Cell Differentiation Antigens. New York, NY: Garland Publishing; 1997:643-645. 46. Sun QH, Liu CY, Newman PJ. CD41/CD61 workshop: disruption of cystine-435 of GPIIIa results in the loss of the epitope for some CD41/CD61 monoclonal antibodies. In: Kishimoto T,Kikutani H,von dem Borne AEGK, et al., eds. Leucocyte Typing VI: White Cell Differentiation Antigens. London United Kingdom: Garland Publishing; 1997:645-647. 47. Mazurov AV, Khaspekova SG, Byzova TV, et al. Stimulation of platelet glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) functional activity by a monoclonal antibody to the N-terminal region of glycoprotein IIIa. FEBS Lett. 1996;391:84-88[CrossRef][Medline] [Order article via Infotrieve].
48.
Shattil SJ, Hoxie JA, Cunningham M, Brass LF.
Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation.
J Biol Chem.
1985;260:11107-11114
49.
Taub R, Gould RJ, Garsky VM, et al.
A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen.
J Biol Chem.
1989;264:259-265 50. Xia Z, Wong T, Liu Q, Kasirer-Friede A, Brown E, Frojmovic MM. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol. 1996;93:204-214[CrossRef][Medline] [Order article via Infotrieve]. 51. Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparation of suspensions of washed platelets from humans. Br J Haematol. 1972;22:193-204[Medline] [Order article via Infotrieve]. 52. Warkentin TE, Powling MJ, Hardisty RM. Measurement of fibrinogen binding to platelets in whole blood by flow cytometry: a micro-method for detection of platelet activation. Br J Haematol. 1990;76:387-394[Medline] [Order article via Infotrieve]. 53. Poujol C, Nurden AT, Nurden P. Ultrastructural analysis of the distribution of the vitronectin receptor (alpha v beta 3) in human platelets and megakaryocytes reveals an intracellular pool and labelling of the alpha-granule membrane. Br J Haematol. 1997;96:823-835[CrossRef][Medline] [Order article via Infotrieve].
54.
Savage B, Shattil SJ, Ruggeri ZM.
Modulation of platelet function through adhesion receptors: a dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor.
J Biol Chem.
1992;267:11300-11306 55. Gao J, Zoller KE, Ginsberg MH, Brugge JS, Shattil SJ. Regulation of the pp72syk protein tyrosine kinase by platelet integrin alpha IIb beta 3. EMBO J. 1997;16:6414-6425[CrossRef][Medline] [Order article via Infotrieve]. 56. Calvete JJ, Henschen A, Gonzalez-Rodriguez J. Assignment of disulphide bonds in human platelet GPIIIa: a disulphide pattern for the beta-subunits of the integrin family. Biochem J. 1991;274:63-71. 57. Jia L, Bonaventura C, Bonaventura J, Stamler JS. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature. 1996;380:221-226[CrossRef][Medline] [Order article via Infotrieve]. 58. Hausladen A, Privalle CT, Keng T, DeAngelo J, Stamler JS. Nitrosative stress: activation of the transcription factor OxyR. Cell. 1996;86:719-729[CrossRef][Medline] [Order article via Infotrieve]. 59. Stamler JS, Toone EJ, Lipton SA, Sucher NJ. (S)No signals: translocation, regulation and a consensus motif. Neuron. 1997;18:691-696[CrossRef][Medline] [Order article via Infotrieve]. 60. Ascenzi P, Colasanti M, Persichini T, et al. Re-evaluation of amino acid sequence and structural consensus rules for cysteine-nitric oxide reactivity. Biol Chem. 2000;381:623-627.
61.
Santoso S, Kalb R, Kroll H, et al.
A point mutation leads to an unpaired cysteine residue and a molecular weight polymorphism of a functional platelet beta 3 integrin subunit: the Sra alloantigen system of GPIIIa.
J Biol Chem.
1994;269:8439-8444
62.
Wang R, Peterson J, Aster RH, Newman PJ.
Disruption of a long-range disulfide bond between residues Cys406 and Cys655 in glycoprotein IIIa does not affect the function of platelet glycoprotein IIb-IIIa.
Blood.
1997;90:1718-1719 63. Milet S, Bourre F, Peyruchaud O, et al. Amino acid substitution Cys457 to Tyr in the beta3 subunit of alphaIIb-beta3 is involved in an atypical case of Glanzmann thrombasthenia [abstract]. Thromb Haemost. 1997;(suppl):360. 64. Nair S, Coller BS, Li J, Mohanty D, French DL. A new GPIIIa mutation that generates an unpaired Cys produces Glanzmann thrombasthenia (GT) and a high molecular weight, disulfide-bonded GPIIIa species [abstract]. Blood. 1998;92:34a.
65.
Ruan J, Schmugge M, Clemetson KJ, et al.
Homozygous Cys542
66.
Grimaldi CM, Chen F, Scudder LE, Coller BS, French DL.
A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta 3) in a Chinese patient with Glanzmann's thrombasthenia.
Blood.
1996;88:1666-1675 67. Ambo H, Kamata T, Handa M, et al. Three novel integrin beta3 subunit missense mutations (H280P, C560F, and G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients. Biochem Biophys Res Commun. 1998;251:763-768[CrossRef][Medline] [Order article via Infotrieve]. 68. Miller JL. Platelet-type von Willebrand disease. Thromb Haemost. 1996;75:865-869[Medline] [Order article via Infotrieve].
69.
Miller JL, Cunningham D, Lyle VA, Finch CN.
Mutation in the gene encoding the
70.
Russel SD, Roth GJ.
Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperreactive surface receptor.
Blood.
1993;81:1787-1791
71.
Dong JF, Schade AJ, Romo GM, et al.
Novel gain-of-function mutations of platelet glycoprotein Ib
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  K. Vanhoorelbeke, S. F. De Meyer, I. Pareyn, C. Melchior, S. Plancon, C. Margue, O. Pradier, P. Fondu, N. Kieffer, T. A. Springer, et al. The Novel S527F Mutation in the Integrin {beta}3 Chain Induces a High Affinity {alpha}IIb{beta}3 Receptor by Hindering Adoption of the Bent Conformation J. Biol. Chem., May 29, 2009; 284(22): 14914 - 14920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Coller and S. J. Shattil The GPIIb/IIIa (integrin {alpha}IIb{beta}3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend Blood, October 15, 2008; 112(8): 3011 - 3025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mor-Cohen, N. Rosenberg, M. Landau, J. Lahav, and U. Seligsohn Specific Cysteines in {beta}3 Are Involved in Disulfide Bond Exchange-dependent and -independent Activation of {alpha}IIb{beta}3 J. Biol. Chem., July 11, 2008; 283(28): 19235 - 19244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ghevaert, A. Salsmann, N. A. Watkins, E. Schaffner-Reckinger, A. Rankin, S. F. Garner, J. Stephens, G. A. Smith, N. Debili, W. Vainchenker, et al. A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the {alpha}IIb{beta}3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia Blood, April 1, 2008; 111(7): 3407 - 3414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Van de Walle, A. Schoolmeester, B. F. Iserbyt, J. M. E. M. Cosemans, J. W. M. Heemskerk, M. F. Hoylaerts, A. Nurden, K. Vanhoorelbeke, and H. Deckmyn Activation of {alpha}IIb{beta}3 is a sufficient but also an imperative prerequisite for activation of {alpha}2{beta}1 on platelets Blood, January 15, 2007; 109(2): 595 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chen, C.-X. Sun, and J.-N. Liu A Novel Anti-platelet Monoclonal Antibody (3C7) Specific for the Complex of Integrin {alpha}IIb{beta}3 Inhibits Platelet Aggregation and Adhesion J. Biol. Chem., July 8, 2005; 280(27): 25403 - 25408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Calvete Structures of Integrin Domains and Concerted Conformational Changes in the Bidirectional Signaling Mechanism of {alpha}IIb{beta}3 Experimental Biology and Medicine, September 1, 2004; 229(8): 732 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chigaev, G. J. Zwartz, T. Buranda, B. S. Edwards, E. R. Prossnitz, and L. A. Sklar Conformational Regulation of {alpha}4{beta}1-Integrin Affinity by Reducing Agents: "INSIDE-OUT" SIGNALING IS INDEPENDENT OF AND ADDITIVE TO REDUCTION-REGULATED INTEGRIN ACTIVATION J. Biol. Chem., July 30, 2004; 279(31): 32435 - 32443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Butta, E. G. Arias-Salgado, C. Gonzalez-Manchon, M. Ferrer, S. Larrucea, M. S. Ayuso, and R. Parrilla Disruption of the {beta}3 663-687 disulfide bridge confers constitutive activity to {beta}3 integrins Blood, October 1, 2003; 102(7): 2491 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lahav, E. M. Wijnen, O. Hess, S. W. Hamaia, D. Griffiths, M. Makris, C. G. Knight, D. W. Essex, and R. W. Farndale Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin {alpha}2{beta}1 Blood, September 15, 2003; 102(6): 2085 - 2092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-H. Sun, C.-Y. Liu, R. Wang, C. Paddock, and P. J. Newman Disruption of the long-range GPIIIa Cys5-Cys435 disulfide bond results in the production of constitutively active GPIIb-IIIa (alpha IIbbeta 3) integrin complexes Blood, August 28, 2002; 100(6): 2094 - 2101. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
IIb
3) integrin
receptor locked in a high-affinity state and a Glanzmann
thrombasthenia-like phenotype
Top
Abstract
Introduction
3-integrin or platelet glycoprotein (GP) IIIa, leading to the
expression of a constitutively activated fibrinogen receptor. The
diagnosis of GT was based on a severely reduced platelet-aggregation response to a series of agonists and approximately 20% of
surface-expressed GPIIb-IIIa. The patient's GPIIb-IIIa
constitutively expressed epitopes recognized by antibodies to
ligand-induced binding sites (LIBS) and also spontaneously bound the
fibrinogen-mimetic antibody, PAC-1. Furthermore, significant
amounts of bound fibrinogen were detected on his platelets ex vivo. No
signs of platelet activation were observed on sections of unstimulated
platelets from N.M. by electron microscopy. Immunogold labeling
highlighted the presence of surface-bound fibrinogen but revealed
platelet heterogeneity with regard to the surface density. When the
patient's platelets were stimulated by thrombin-receptor activating
peptide, amounts of surface-expressed GPIIb-IIIa
increased and the aggregation response improved, although it
failed to normalize. Platelets from N.M. were able to adhere and spread
on immobilized fibrinogen. Sequence analysis of genomic DNA from N.M.
revealed a homozygous g1776T>C mutation in GPIIIa, leading to
a Cys560Arg amino acid substitution. A stable Chinese hamster ovary
(CHO) cell line was prepared expressing surface
GPIIb-Arg560IIIa. Like platelets from the patient,
GPIIb-Arg560IIIa-transfected CHO cells constitutively bound LIBS
antibodies and PAC-1. They also showed an enhanced ability to adhere on
surface-bound fibrinogen. Overall, these data demonstrate that
a gain-of-function mutation can still be associated with a
thrombasthenic phenotype even though platelets show spontaneous
fibrinogen binding.
(Blood. 2001;98:2432-2441)
Fix)/(Fm
RII blocking antibody, IV.3
(Medarex, Annandale, NJ), as described previously by Warkentin et
al.
Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia.
Proc Natl Acad Sci U S A.
1992;89:10169-10173